

## We Need to Rehabilitate the Brains of Individuals with Parkinson's Disease: The Incredible Gains with Transcranial Direct Current Electrostimulation (tDCS)

Fracasso BV<sup>1\*</sup> and Malysz T<sup>1,2</sup>

<sup>1</sup>Postgraduate Program in Neurosciences, Institute of Basic Health Sciences (ICBS), Federal University of Rio Grande do Sul (UFRGS), Brazil

<sup>2</sup>Department of Morphological Sciences, Institute of Basic Health Sciences (ICBS), Federal University of Rio Grande do Sul (UFRGS), Brazil

### \*Corresponding author:

Bruno Veloso Fracasso,  
Postgraduate Program in Neurosciences, Institute of  
Basic Health Sciences (ICBS), Federal University  
of Rio Grande do Sul (UFRGS), Brazil

Received: 10 Nov 2023

Accepted: 19 Dec 2023

Published: 27 Dec 2023

J Short Name: ACMCR

### Copyright:

©2023 Fracasso BV. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially

### Citation:

Fracasso BV, We Need to Rehabilitate the Brains of Individuals with Parkinson's Disease: The Incredible Gains with Transcranial Direct Current Electrostimulation (tDCS). *Ann Clin Med Case Rep.* 2023; V12(7): 1-3

### Keywords:

Substantia; Parkinsonian; Bradykinesia

## 1. Case Report

Parkinsonian syndromes are determined by the presence of at least two of the four main symptoms: bradykinesia, rigidity, resting tremor and postural instability [2, 18], caused by a reduction in dopamine in the pars Compacta of the substantia nigra [6]. Among the primary forms, Parkinson's disease (PD) stands out as the most common parkinsonian syndrome. Bradykinesia, or slowness of movement, is the most characteristic motor symptom [1] and is the main reason for functional changes in patients [27]. Tremor initially appears unilateral and progresses to bilateral, worsening in stressful circumstances or cognitive tasks, and may be attenuated during sleep or movement [10]. Stiffness, a hypertonic muscle characteristic, causes constant or oscillating resistance to passive joint movement and can be increased by tasks that require attention [13]. This sum of physical factors, also linked to conditions of cognitive decline resulting from a basically neurodegenerative disease, is capable of negatively interfering with the biopsychosocial components of its sufferers [29].

Studies that address PD epidemiological data such as prevalence, for example, are scarce in the world due to underreporting [30]. However, it is known that sociodemographic evolution leads to the emergence of diseases related to aging/neurodegeneration, in which PD is considered the second pathology with the highest in-

cidence, affecting one in every 100 people over 60 years of age [17]. PD treatment can be subdivided into medication for motor and non-motor symptoms, prescription of neuroprotectors and surgeries, in addition to therapies such as physiotherapy, speech therapy, occupational therapy and other complementary and integrative therapies [11, 23].

In this sense, disorders related to balance, gait and posture are common in PD and have a significant influence on the functionality of individuals. Therefore, a thorough assessment that seeks to understand functional capabilities is essential to initiate appropriate treatment strategies, aiming to reduce limitations and, consequently, improve the quality of life of this population [28]. The word "disabilities" is used by the World Health Organization (WHO) to describe changes in the body that affect the individual's activities and social participation [34]. In other words, it refers to those people who face limitations due to disabilities and/or chronic illnesses, such as PD. This definition considers the fact that people with the same clinical condition may have different levels of functionality, just as individuals with the same level of functionality do not necessarily have the same health condition [34]. Furthermore, according to the WHO [35], globally disability and death due to PD are increasing faster than for any other neurological disorder, with an increase greater than 100% in these outcomes, from 2000

to 2019.

Transcranial Direct Current Stimulation (tDCS) consists of applying direct current to the scalp using electrodes wrapped in perforated sponge bags soaked in saline solution or rubber electrodes with conductive gel [9]. This technique modulates neural activity through electrical currents that, when applied as a direct current component, polarize neural tissue, inducing significant changes in the resting membrane potential threshold and subsequent modifications in synaptic plasticity [8]. Depending on the size and polarity of the conducting electrodes, current intensity, density and duration of stimulation, it is capable of inducing changes in cortical excitability [24].

For example, according to Polanía, Paulus and Nitsche [26], the application of anodal tDCS promotes depolarization, while cathodal tDCS promotes cellular hyperpolarization. The technique has also been attributed to lasting changes in the excitability of the motor cortex in humans and tDCS has been successfully studied in depression [4, 5], chronic pain [14], accident cerebrovascular disease [31], Alzheimer's disease [15], in addition to findings in PD [33] and other neurological and neuropsychiatric conditions such as schizophrenia, obsessive compulsive disorder and chemical dependency [16]. Furthermore, studies show that positioning the electrode over different areas of the cortex is essential to determine the direction and spatial distribution of the current flow and, ultimately, the effectiveness of the treatment according to the pathophysiological mechanism of the disease treated [9, 32].

In 2006, Fregni et al [12] observed that the motor evoked potential, both anodal tDCS and cathodal tDCS in the left dorsolateral prefrontal cortex, caused an immediate change in the excitability of the motor cortex after the stimulus; however, the UPDRS (Unified Parkinson's Disease Rating Scale) results showed that only anodal tDCS promoted significant improvement in the comprehensive motor function of PD patients. Subsequently, experimental studies sought to understand the mechanisms involved in the use of the technique in PD and found that tDCS induced the release of dopamine in the caudate nucleus [19, 21]. Furthermore, it was found that tDCS also modulates the functional connectivity of thalamo-cortical circuits, having positive effects on neuroplasticity, motor control and learning [25, 26]. According to Oliveira et al (2022), studies indicate that the use of tDCS early, in relation to diagnosis, reduces cadence, upper limb bradykinesia, freezing of gait and improvement of levodopa-induced dyskinesia.

The dorsolateral prefrontal cortex (DLPFC) has been an area of interest in the application of tDCS in individuals whose therapeutic objective involves cognitive aspects [16]. However, it is also proposed to use it in motor conditions, as cognitive functions are necessary to perform motor tasks and are partially modulated by the DLPFC [23]. In a systematic review that evaluated the use of tDCS on cognitive changes in people with Alzheimer's and PD,

it was seen that in patients with PD, executive efficiency was improved thanks to the stimulation of DLPFC through variable treatment sessions (i.e., 1 to 10 sessions) with an intensity of 1 to 2 mA for 20 minutes [6, 22]. Merzagora et al [22] compare the acute effects of tDCS on DLPFC using anode and cathode current for 10 minutes; the authors observed the ability to cause a significant increase in oxyhemoglobin concentrations in this area when stimulated with anodic current, whereas no changes were seen when stimulated with cathodic current. Chang et al [7] also targeted the left DLPFC, using anodic current and observed positive results on participants' freezing of gait events.

When evaluating the acute effects of tDCS on healthy individuals, Lima [20], found that mounting the tDCS in the DLPFC position did not induce deleterious neurovegetative changes, demonstrating that it is a safe application method. Therefore, we found a favorable scientific scenario with very satisfactory results with the use of tDCS in the treatment of people with PD. Furthermore, it must be said that it is a painless treatment, with minimal side effects (itching at the site of application which ends when the therapy ends), non-invasive and cheap, which makes the technique democratic and accessible to a large number of people. part of the population.

## References

1. Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, et al. Critérios da Sociedade de Distúrbios do Movimento para a doença de Parkinson inicial clinicamente estabelecida. *Mova a desordem*. 2018; 33: 1643-6.
2. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. *Movement Disorders*. 2014; 29(4): 454-62.
3. Boggio PS, Ferrucci R, Rigonatti SP, Covre P, Nitsche M, Pascual-Leone A, et al. Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. *Journal of the neurological sciences*. 2006; 249: 31-8.
4. Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, et al. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. *International Journal of Neuropsychopharmacology*. 2008; 11(2): 249-54.
5. Brunelin J, Mondino M, Haesebaert F, Saoud M, Suaud-Chagny MF, Poulet E. Efficacy and safety of bifocal ETCC as an interventional treatment for refractory schizophrenia. 2012.
6. Cammisuli DM, Cignoni F, Ceravolo R, Bonuccelli U, Castelnovo G. Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. *Frontiers in Neurology*. 2022; 12: 2648.

7. Chang WH, Kim MS, Park E, Cho JW, Youn J, Kim YK, et al. Effect of Dual-Mode and Dual-Site Noninvasive Brain Stimulation on Freezing of Gait in Patients With Parkinson Disease. *Archives of Physical Medicine and Rehabilitation*. 2017; 98(7): 1283-90.
8. Cioato SG, Medeiros LF, Marques Filho PR, Vercelino R, de Souza A, Scarabelot VL, et al. Long-lasting effect of transcranial direct 26 current stimulation in the reversal of hyperalgesia and cytokine alterations induced by the neuropathic pain model. *Brain stimulation*. 2016; 9(2): 209-17.
9. Dalla Volta G, Marceglia S, Zavarise P, Antonaci F. Cathodal ETCC guided by thermography as adjunctive therapy in chronic migraine patients: a shamcontrolled pilot study. *Frontiers in Neurology*. 2020; 11.
10. DeMaagd G, Philip A. Doença de Parkinson e seu manejo: parte 1: entidade da doença, fatores de risco, fisiopatologia, apresentação clínica e diagnóstico. *P T*. 2015; 40: 504-32.
11. Dong J, Cui Y, Li S, Le W. Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease. *Current Neuropharmacology*. 2016; 14(4).
12. Fregni F, Boggio PS, Santos MC, Lima M, Vieira AL, Rigonatti SP, et al. Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. *Mov. Disord*. 2006; 21: 1693-702.
13. Hallett M, Hess C. A fenomenologia da doença de Parkinson. *Semin Neurol*. 2017; 37: 109-17.
14. Jales Junior LH, Costa MDDL, Jales Neto LH, Ribeiro JPM, Freitas, Jankovic J. Parkinsonism-plus syndromes. *Mov. Disord*. 1989; 4 (Suppl 1) S95-S119.
15. Khedr EM, Gamal NFE, El-Fetoh NA, Khalifa H, Ahmed EM, Ali AM, et al. A double-blind randomized clinical trial on the efficacy of cortical direct current stimulation for the treatment of Alzheimer's disease. *Frontiers in aging neuroscience*. 2014; 6: 275.
16. Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, et al. Evidence-based guidelines on the 27 therapeutic use of transcranial direct current stimulation (ETCC). *Clinical Neurophysiology*. 2017; 128(1): 56-92.
17. Leiva AM, Martinez-Sanguinetti MAM, Troncoso-Pantoja C, Nazar G, Petermann-Rocha F, Celis-Morales C. Chile lidera el ranking latinoamericano de prevalencia de enfermedad de Parkinson. *Revista de Medicina Chile*. 2019; 147(4).
18. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The Differential Diagnosis and Treatment of Atypical Parkinsonism. *Deutsches Arzteblatt international*. 2016; 113(5): 61-9.
19. Li H, Lei X, Yan T, Li H, Huang B, Li L, et al. The temporary and accumulated effects of transcranial direct current stimulation for the treatment of advanced Parkinson's disease monkeys. *Scientific reports*. 2015; 5: 1-10.
20. Lima, Keite Oliveira de. Avaliação dos efeitos agudos da estimulação transcraniana por corrente direta em indivíduos saudáveis: um estudo randomizado, single-blind, placebo-controlado. 2013.
21. Lu C, Wei Y, Hu R, Wang Y, Li K, Li X. Transcranial direct current stimulation ameliorates behavioral deficits and reduces oxidative stress in 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine-induced mouse model of Parkinson's disease. *Neuromodulation: Technology at the Neural Interface*. 2015; 18(6): 442-7.
22. Merzagora AC, Foffani G, Panyavin I, Mordillo-Mateos L, Aguilar J, Onaral B, et al. Prefrontal hemodynamic changes produced by anodal direct current stimulation. *NeuroImage*. 2010; 49: 2304-10.
23. Mishra R Kinker, Thrasher AT. Transcranial direct current stimulation of dorsolateral prefrontal cortex improves dual-task gait performance in patients with Parkinson's disease: A double blind, sham-controlled study. *Gait Posture*. 2021; 84: 11-6.
24. Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. *The Journal of physiology*. 2000; 527(3): 633-9.
25. Orban De Xivry JJ, Shadmehr R. Electrifying the motor engram: effects of tDCS on motor learning and control. *Experimental Brain Research*. 2014; 232: 3379-95.
26. Polanía R, Paulus W, Nitsche MA. Modulating cortico-striatal and thalamo-cortical functional connectivity with transcranial direct current stimulation. *Human brain mapping*. 2012; 33(10): 2499-508.
27. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. Critérios diagnósticos clínicos da SMD para a doença de Parkinson. *Mova a desordem*. 2015; 30: 1591-601.
28. Raccagni C, Nonnekes J, Bloem BR, Peball M, Boehme C, Seppi K, et al. Gait and postural disorders in parkinsonism: a clinical approach. *Journal of neurology*. 2019; 1-8.
29. Rocha, Amanda Dantas Reis; Silva, Karina Martins Rodrigues. Avaliação da qualidade de vida nos estágios da doença de parkinson e correlação com o grau de incapacidade, risco de quedas e atividades de vida diária. *Repositório Institucional do UNILUS*. 2023; 2: 1.
30. Santos, Giovanni Ferreira et al. Doença de Parkinson: Padrão epidemiológico de internações no Brasil. *Pesquisa, Sociedade e Desenvolvimento*. 2022; 11: e13511124535-e13511124535.
31. Sattler V, Acket B, Raposo N, Albuchoer JF, Thalamas C, Loubinoux I, et al. Anodal ETCC combined with radial nerve stimulation promotes hand motor recovery in the acute phase after ischemic stroke. *Neurorehabilitation and neural repair*. 2015; 29(8): 743-54.
32. Utz KS, Dimova V, Oppenländer K, Kerkhoff G. Electrified minds: transcranial direct current stimulation (ETCC) and galvanic vestibular stimulation (GVS) as methods of non-invasive brain stimulation in neuropsychology—a review of current data and future implications. *Neuropsychologia*. 2010; 48(10): 2789-810.
33. Valentino F, Cosentino G, Brighina F, Pozzi NG, Sandrini G, Fierro B, et al. Transcranial direct current stimulation for treatment of freezing of gait: A cross-over study. *Movement Disorders*. 2014; 29(8): 1064-9.
34. WHO, World Health Organization. *International Classification of Functioning, Disability and Health: ICF*. Geneva: WHO. 2001.
35. World Health Organization. *Parkinson disease: a public health approach: technical brief*. 2022.